EMERALD-3 Roundtable: Hepatocellular Carcinoma Trial Breakdown & Insights

Community Health Media · Jun 25, 2026 · 1h 14m

Could EMERALD-3 redefine the treatment paradigm for unresectable hepatocellular carcinoma?

In this special roundtable discussion recorded at ASCO 2026, Dr. Ghassan Abou-Alfa is joined by Dr. Gentry King, Dr. Mehmet Akce, Dr. Pierre Gholam, Dr. Lingling Du, Dr. Adam Burgoyne, Dr. Lipika Goyal, and Dr. Riad Salem to break down the landmark EMERALD-3 study.

The panel explores the scientific rationale for combining transarterial chemoembolization (TACE) with immunotherapy and antiangiogenic therapy, while reviewing key efficacy findings from the EMERALD-3 study. Beyond the data, the experts…